Advertisement
ANAB vs LNAI
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANAB is a StrongBuy and LNAI is a Hold.
ANAB's RSI Indicator recovers from oversold territory
The RSI Indicator for ANAB moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 21 similar instances when the indicator left oversold territory. In 20 of the 21 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 60 cases where ANAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ANAB as a result. In 75 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for ANAB just turned positive on October 15, 2026. Looking at past instances where ANAB's MACD turned positive, the stock continued to rise in 42 of 52 cases over the following month. The odds of a continued upward trend are 81%.
Following a +1.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANAB advanced for three days, in 221 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
ANAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ANAB entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. ANAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ANAB's P/B Ratio (114.379) is very high in comparison to the industry average of (3.037). P/E Ratio (-47.814) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (6.614) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
LNAI's RSI Oscillator stays in oversold zone for 20 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +9.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where LNAI advanced for three days, in 182 of 211 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
LNAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LNAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for LNAI entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.131) is normal, around the industry mean (3.037). P/E Ratio (-0.004) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (294.118) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. LNAI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LNAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ANAB | LNAI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 37 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 45 | 98 | |
P/E GROWTH RATING 1..100 | 35 | 5 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LNAI's Valuation (53) in the Financial Conglomerates industry is somewhat better than the same rating for ANAB (94) in the Biotechnology industry. This means that LNAI’s stock grew somewhat faster than ANAB’s over the last 12 months.
ANAB's Profit vs Risk Rating (37) in the Biotechnology industry is somewhat better than the same rating for LNAI (100) in the Financial Conglomerates industry. This means that ANAB’s stock grew somewhat faster than LNAI’s over the last 12 months.
ANAB's SMR Rating (99) in the Biotechnology industry is in the same range as LNAI (100) in the Financial Conglomerates industry. This means that ANAB’s stock grew similarly to LNAI’s over the last 12 months.
ANAB's Price Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for LNAI (98) in the Financial Conglomerates industry. This means that ANAB’s stock grew somewhat faster than LNAI’s over the last 12 months.
LNAI's P/E Growth Rating (5) in the Financial Conglomerates industry is in the same range as ANAB (35) in the Biotechnology industry. This means that LNAI’s stock grew similarly to ANAB’s over the last 12 months.
| ANAB | LNAI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 85% | N/A |
| Momentum ODDS (%) | 2 days ago 80% | N/A |
| MACD ODDS (%) | 2 days ago 81% | N/A |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| Advances ODDS (%) | 2 days ago 79% | 7 days ago 86% |
| Declines ODDS (%) | 21 days ago 81% | 2 days ago 90% |
| BollingerBands ODDS (%) | 5 days ago 77% | 2 days ago 89% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANAB’s FA Score shows that 0 FA rating(s) are green while LNAI’s FA Score has 1 green FA rating(s).
- ANAB’s FA Score: 0 green, 5 red.
- LNAI’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANAB’s TA Score shows that 6 TA indicator(s) are bullish while LNAI’s TA Score has 3 bullish TA indicator(s).
- ANAB’s TA Score: 6 bullish, 2 bearish.
- LNAI’s TA Score: 3 bullish, 2 bearish.
Price Growth
ANAB (@Biotechnology) experienced а -0.95% price change this week, while LNAI (@Biotechnology) price change was -41.75% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.61%. For the same industry, the average monthly price growth was -10.44%, and the average quarterly price growth was -13.24%.
Reported Earning Dates
ANAB is expected to report earnings on Nov 03, 2026.
LNAI is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (+4.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
LNAI and
Correlation & Price change
A.I.dvisor indicates that over the last year, LNAI has been closely correlated with CANF. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if LNAI jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To LNAI | 1D Price Change % | ||
|---|---|---|---|---|
| LNAI | 100% | -6.65% | ||
| CANF - LNAI | 72% Closely correlated | -3.37% | ||
| APVO - LNAI | 60% Loosely correlated | -6.25% | ||
| GNPX - LNAI | 56% Loosely correlated | N/A | ||
| ICU - LNAI | 55% Loosely correlated | +2.49% | ||
| MLEC - LNAI | 48% Loosely correlated | -11.63% | ||
More | ||||